<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039312</url>
  </required_header>
  <id_info>
    <org_study_id>99-10-034</org_study_id>
    <secondary_id>UCLA-9910034</secondary_id>
    <secondary_id>NCI-G02-2076</secondary_id>
    <nct_id>NCT00039312</nct_id>
  </id_info>
  <brief_title>Comparison of Screening Tests in Detecting Cervical Neoplasia</brief_title>
  <official_title>Multi-Institutional Prospective Cohort Study For The Comparison Of Different Primary Screening Strategies For The Detection Of Cervical Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Screening tests may help doctors detect abnormal cells in the cervix early and&#xD;
      plan effective treatment.&#xD;
&#xD;
      PURPOSE: Screening trial to compare different types of screening tests used to detect&#xD;
      cervical neoplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the sensitivity and specificity of primary screening strategies for the&#xD;
           detection of cervical intraepithelial or invasive neoplasia.&#xD;
&#xD;
        -  Compare the positive and negative predictive values of these strategies.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to the reason for the&#xD;
      visit (general gynecological screening vs colposcopy referral).&#xD;
&#xD;
        -  Stratum 1 (general gynecological screening): Patients undergo Pap smear, visual&#xD;
           inspection aided by acetic acid (VIA), a colposcopy, and finally a visual inspection&#xD;
           aided by toluidine blue (VIT) followed by an acetic acid wash. A biopsy may be performed&#xD;
           at this initial visit. Within 2-3 weeks, patients are notified of results.&#xD;
&#xD;
        -  Stratum 2 (colposcopy referral): Patients undergo Pap smear, VIA, colposcopy, VIT, and&#xD;
           possible biopsy as in stratum 1. During the same visit, patients receive histologic&#xD;
           evaluation and treatment with See-and-Treat loop electrosurgical excision procedure&#xD;
           and/or endocervical curettage.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 600-1,000 patients (300-500 per stratum) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">15</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Papanicolaou test</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>annual screening</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colposcopic biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>comparison of screening methods</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria::&#xD;
&#xD;
          -  History of cervical neoplasia&#xD;
&#xD;
          -  Presenting for a well-woman visit, annual Pap smear, or family planning&#xD;
&#xD;
               -  Other gynecological or non-gynecological complaints allowed OR&#xD;
&#xD;
          -  Referred for colposcopy secondary to an abnormal Pap smear&#xD;
&#xD;
          -  Planned screening for cervical cancer&#xD;
&#xD;
          -  Over 18 years of age&#xD;
&#xD;
          -  Prior laser surgery, cryotherapy, or conization or loop electrosurgical excision&#xD;
             procedure for cervical neoplasia allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  bleeding diathesis&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  prior hysterectomy&#xD;
&#xD;
          -  concurrent anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Holschneider, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

